Free Trial

Inhibikase Therapeutics (IKT) Competitors

Inhibikase Therapeutics logo
$1.89 +0.04 (+2.16%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IKT vs. TYRA, MAZE, VALN, SEPN, ATYR, MREO, CGEM, AMLX, ZYBT, and ORKA

Should you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include Tyra Biosciences (TYRA), Maze Therapeutics (MAZE), Valneva (VALN), Septerna (SEPN), aTyr Pharma (ATYR), Mereo BioPharma Group (MREO), Cullinan Therapeutics (CGEM), Amylyx Pharmaceuticals (AMLX), Zhengye Biotechnology (ZYBT), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry.

Inhibikase Therapeutics vs. Its Competitors

Inhibikase Therapeutics (NYSE:IKT) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Tyra Biosciences' return on equity of -26.90% beat Inhibikase Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Inhibikase TherapeuticsN/A -350.63% -201.82%
Tyra Biosciences N/A -26.90%-25.54%

Inhibikase Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500.

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 7.3% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 15.2% of Tyra Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Tyra Biosciences had 2 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 6 mentions for Tyra Biosciences and 4 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.30 beat Tyra Biosciences' score of 0.03 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inhibikase Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tyra Biosciences
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Tyra Biosciences is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.71
Tyra BiosciencesN/AN/A-$86.48M-$1.63-6.13

Inhibikase Therapeutics currently has a consensus price target of $6.50, indicating a potential upside of 243.92%. Tyra Biosciences has a consensus price target of $30.83, indicating a potential upside of 208.49%. Given Inhibikase Therapeutics' higher probable upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Tyra Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inhibikase Therapeutics
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Tyra Biosciences
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Tyra Biosciences beats Inhibikase Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Inhibikase Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IKT vs. The Competition

MetricInhibikase TherapeuticsBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$140.51M$202.67M$5.50B$20.64B
Dividend YieldN/AN/A5.38%3.74%
P/E Ratio-0.71N/A27.6028.10
Price / SalesN/A223.65369.5454.30
Price / CashN/A22.4436.6322.31
Price / Book1.065.618.054.59
Net Income-$19.03M-$96.61M$3.18B$986.06M
7 Day Performance16.67%-0.63%2.82%2.79%
1 Month Performance-4.55%-0.97%3.69%5.41%
1 Year Performance64.28%16.23%35.41%14.62%

Inhibikase Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IKT
Inhibikase Therapeutics
1.405 of 5 stars
$1.89
+2.2%
$6.50
+243.9%
+64.3%$140.51MN/A-0.716News Coverage
TYRA
Tyra Biosciences
1.8354 of 5 stars
$9.71
+5.2%
$30.83
+217.5%
-41.1%$490.02MN/A-5.9620Analyst Forecast
MAZE
Maze Therapeutics
N/A$10.73
-4.0%
$25.67
+139.2%
N/A$489.65M$167.50M0.00121
VALN
Valneva
1.6582 of 5 stars
$5.56
-1.1%
$15.50
+178.8%
-20.5%$478.23M$183.52M-4.67700Positive News
SEPN
Septerna
1.7059 of 5 stars
$10.53
+0.6%
$26.75
+154.0%
N/A$466.53M$1.08M0.00N/A
ATYR
aTyr Pharma
2.9999 of 5 stars
$4.98
-4.6%
$20.20
+305.6%
N/A$464.60M$230K-6.1553High Trading Volume
MREO
Mereo BioPharma Group
1.9919 of 5 stars
$2.74
-3.9%
$7.60
+177.4%
-19.9%$453.15M$10M-39.1440
CGEM
Cullinan Therapeutics
1.5423 of 5 stars
$7.58
-1.2%
$30.00
+295.8%
-53.5%$452.64MN/A-2.6030
AMLX
Amylyx Pharmaceuticals
3.5177 of 5 stars
$5.02
-0.6%
$10.14
+102.0%
+255.9%$450.16M$87.37M-1.61200
ZYBT
Zhengye Biotechnology
N/A$7.43
-20.1%
N/AN/A$438.65MN/A0.00278News Coverage
Lockup Expiration
ORKA
Oruka Therapeutics
2.228 of 5 stars
$10.90
-6.7%
$40.38
+270.4%
N/A$437.30MN/A-2.42N/ANews Coverage

Related Companies and Tools


This page (NYSE:IKT) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners